

FOI 1739

05.07.2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1 - How many patients has your Trust treated in the past 3 months for:

- **Non-small cell lung cancer (NSCLC) - any treatment** – information not held
- **Non-small cell lung cancer (NSCLC) - surgical treatment** – information not held
- **Non-small cell lung cancer (NSCLC) – radiotherapy** – information not held
- **Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT)**
– information not held

Q2 - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **ALK Inhibitors:**
 - Alectinib** - <5
 - Brigatinib** – 0
 - Ceritinib** – 0
 - Crizotinib** – 0
 - Lorlatinib** – 0
- **Amivantamab** – 0
- **Atezolizumab monotherapy** - 0
- **Atezolizumab with chemotherapy** - 0
- **Dabrafenib + Trametinib** - 0
- **Durvalumab** – <5
- **Gemcitabine** - 0
- **Nitendanib + Docetaxel** - 0
- **Nivolumab** - 0
- **Osimertinib** – 6
- **Other EGFR Inhibitors:**
 - Afatinib** - 0
 - Erlotinib** – <5
 - Gefitinib** - 0
 - Dacomitinib** - 0
 - Mobocertinib** - 0
- **Paclitaxel** - <5

- **Pembrolizumab monotherapy – 14**
- **Pembrolizumab with chemotherapy – 5**
- **Pemetrexed with carboplatin/cisplatin – 10**
- **RET Inhibitors (Pralsetinib, Selpercatinib) - 0**
- **Sotorasib - 0**
- **Tepotinib - 0**
- **Vinorelbine monotherapy or combination with Carboplatin/Cisplatin - 0**
- **Other active systemic anti-cancer therapy [please state] – Docetaxel <5**
- **Palliative care only – information not held**

Q3 - Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab? – N/A

Please note:

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net